Department of Pediatrics, Boston Medical Center, Boston, Massachusetts.
Boston University School of Medicine, Boston, Massachusetts.
Am J Perinatol. 2024 May;41(S 01):e2970-e2977. doi: 10.1055/a-2183-9109. Epub 2023 Sep 29.
The Advisory Committee on Immunization Practices and The American College of Obstetricians and Gynecologists recommend coronavirus disease 2019 (COVID-19) vaccine for pregnant persons to prevent severe illness and death. The objective was to examine levels of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG, IgM, and IgA against spike protein receptor binding domain (RBD) and nucleocapsid protein (NCP) in maternal and infant/cord blood at delivery after COVID 19 vaccination compared with SARS-CoV-2 infection at in mother-infant dyads at specified time points.
Mothers with SARS-CoV-2 infection ( = 31) or COVID-19 vaccination ( = 25) during pregnancy were enrolled between July 2020 and November 2021. Samples were collected at delivery and IgG, IgM, and IgA to RBD of spike and NCPs compared in the infected and vaccinated groups. Timing of infection/vaccination prior to delivery and correlation with antibody levels was performed.
The majority of participants received vaccination within 90 days of delivery and over half received the Pfizer BioNTech vaccine. There were no significant correlations between antibody levels and timing of infection or vaccination. Infant IgG levels to the RBD domain of spike protein were higher in the vaccinated group ( = 25) as compared with the infants born to mothers with infection ( = 31). Vaccination against COVID-19 during pregnancy was associated with detectable maternal and infant anti-RBD IgG levels at delivery irrespective of the timing of vaccination.
Timing of vaccination had no correlation to the antibody levels suggesting that the timing of maternal vaccination in the cohort did not matter. There was no IgM detected in infants from vaccinated mothers. Infants from vaccinated mothers had robust IgG titers to RBD, which have a lasting protective effect in infants.
· COVID-19 vaccination during pregnancy had detectable antibody.. · No correlation between antibody levels and timing of vaccination.. · Infants from vaccinated mothers had robust IgG titers to RBD..
免疫实践咨询委员会和美国妇产科医师学会建议孕妇接种 2019 冠状病毒病（COVID-19）疫苗，以预防重症和死亡。本研究旨在比较 COVID-19 疫苗接种和 SARS-CoV-2 感染后母亲和婴儿/脐带血中针对刺突蛋白受体结合域（RBD）和核衣壳蛋白（NCP）的严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）IgG、IgM 和 IgA 水平，并在特定时间点对母婴对子进行 SARS-CoV-2 感染的比较。
2020 年 7 月至 2021 年 11 月期间，招募了 SARS-CoV-2 感染（ = 31）或 COVID-19 疫苗接种（ = 25）的孕妇。在分娩时采集样本，并比较感染组和接种组中针对刺突 RBD 和 NCP 的 IgG、IgM 和 IgA。还进行了感染/接种前的时间与抗体水平的相关性分析。
大多数参与者在分娩前 90 天内接种疫苗，超过一半的人接种了辉瑞 BioNTech 疫苗。抗体水平与感染或接种时间之间没有显著相关性。与感染母亲所生婴儿（ = 31）相比，接种疫苗的婴儿（ = 25）对刺突蛋白 RBD 域的 IgG 水平更高。无论接种时间如何，孕妇在怀孕期间接种 COVID-19 疫苗与分娩时可检测到的母婴抗 RBD IgG 水平相关。
接种时间与抗体水平没有相关性，这表明该队列中母亲接种疫苗的时间并不重要。从接种疫苗的母亲所生的婴儿中未检测到 IgM。从接种疫苗的母亲所生的婴儿对 RBD 具有强大的 IgG 滴度，这对婴儿具有持久的保护作用。
· 孕妇接种 COVID-19 疫苗可产生抗体。· 抗体水平与接种时间无相关性。· 从接种疫苗的母亲所生的婴儿对 RBD 具有强大的 IgG 滴度。
